Jagsonpal Pharmaceuticals has signed a definitive agreement to acquire an 85 percent equity stake in Mumbai-based Aequitas Healthcare for INR 20.8 crore, marking its entry into India's hospital pharmaceutical segment.

The acquisition, which will be funded through Jagsonpal's internal accruals, is aligned with the company's long-term strategy to strengthen its presence across the country's evolving healthcare landscape. Following the transaction, the existing directors of Aequitas Healthcare will retain the remaining 15 percent stake and continue to manage and support the business.

Aequitas Healthcare primarily focuses on the sale and distribution of pharmaceutical products to hospitals and has built a strong institutional presence since its inception.

Commenting on the acquisition, Manish Gupta, Managing Director of Jagsonpal Pharmaceuticals, said the transaction represents a significant strategic milestone for the company by providing an established platform in the hospital segment, which now contributes around 10 percent of India's pharmaceutical industry sales and continues to grow at a faster pace than the broader market.

He added that Jagsonpal expects its portfolio of established pharmaceutical brands to benefit from Aequitas' strong institutional relationships, creating sustainable long-term value for shareholders.

Amrut Medhekar, Chief Operating Officer of Jagsonpal Pharmaceuticals, described the acquisition as a transformative step that will reposition the company from a traditional retail prescription-focused business to an omnichannel specialty healthcare player. He said the move reflects Jagsonpal's commitment to building a scalable, patient-centric healthcare business through operational excellence and disciplined execution.

Shailesh Kamat, Director and the largest shareholder of Aequitas Healthcare, said the company has built a strong hospital-focused business over the past eight years through a quality product portfolio, deep institutional partnerships and a dedicated team. He noted that partnering with Jagsonpal Pharmaceuticals would help accelerate the company's next phase of growth while creating new opportunities for employees, customers and the broader healthcare ecosystem.

The acquisition is subject to customary closing conditions and is expected to be completed by July 15, 2026.